【摘要】：正由中國藥科大學(xué)醫(yī)藥化工研究所朱雄、吳葆金研究員負(fù)責(zé)研發(fā),具有自主知識(shí)產(chǎn)權(quán)的國家Ⅰ類抗腫瘤新藥去氧鬼臼毒素及其注射劑經(jīng)過長達(dá)八年的艱苦努力,日前順利通過了國家食品藥品監(jiān)督管理總局審批,獲得了CFDA頒發(fā)的Ⅰ~Ⅲ期藥物臨床研究批件,這是中國藥科大學(xué)在創(chuàng)新藥研究領(lǐng)域取得的又一重要成果。去氧鬼臼毒素(以下簡稱DPT)是從中藥中提取的有效成分,自然界存在于桃兒七等藥用植物中,但含量極微,且在
[Abstract]:The deoxypodophyllotoxin and its injection, a national class I antitumor drug with independent intellectual property rights, is being developed by Zhu Xiong, Institute of Pharmaceutical and Chemical Research, China University of Pharmacy, and Wu Baojin, a researcher in charge of the research and development, after eight years of hard work. The approval of the State Administration of Food and Drug Administration was successfully approved by the State Administration of Food and Drug Administration a few days ago, and the approval of the phase 鈪，

本文編號(hào)：2278709